17 February 2023 - - US-based human stem cell-based platforms developer Curi Bio has appointed Nicholas A. Geisse, Ph.D. as chief executive officer, effective immediately, the company said.

Dr. Geisse has been serving as the chief science officer at Curi Bio since 2017. During that time, he was responsible for guiding the company's scientific strategy and the commercialization of its next-generation products that greatly improve the predictive power of in vitro cell-based assays.

Dr. Geisse succeeds Michael Cho, J.D., who will continue on with the company in a role focusing on corporate strategy and legal matters.

Dr. Geisse completed his undergraduate degree in Biochemistry and Molecular Biology at Boston University, followed by his Ph.D. in Pharmacology from Cambridge University in England under Dr. RM Henderson.

He continued his studies in tissue engineering and instrumentation development with a postdoctoral fellowship in cardiac cell and tissue engineering at the Harvard University School of Engineering and Applied Sciences under Prof. Kevin Kit Parker.

After his postdoc, he worked in a variety of scientific, commercial, product development, and management roles for Asylum Research (acquired by Oxford Instruments in December 2012).

Dr. Geisse's work at Curi Bio has been recognized by several national awards, including Xconomy's 2020 'Big Idea' award, the US Small Business Administration's 2020 Tibbetts award, and 2021 Edison Award.

Dr. Geisse has also led an active R&D program at Curi Bio that is supported by customer partnerships and a number of SBIR grants from the National Institutes of Health.

Curi Bio's preclinical discovery platform combines human stem cells, systems, and data to accelerate the discovery of new medicines.

The Curi Engine is a comprehensive, bioengineered platform that integrates human iPSC-derived cell models, tissue-specific biosystems, and AI/ML-enabled phenotypic screening data.

Curi Bio's suite of human stem cell-based products and services enable scientists to build more mature and predictive human iPSC-derived tissues--with a focus on cardiac, musculoskeletal, and neuromuscular models--for the discovery, safety testing, and efficacy testing of new drugs in development.

By offering drug developers an integrated preclinical platform comprising highly predictive human stem cell models to generate clinically-relevant data, Curi Bio is closing the gap between preclinical data and human results, accelerating the discovery and development of safer, more effective medicines.